SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Safety profile of tofersen in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the safety profile of tofersen in patients with SOD1-associated amyotrophic lateral sclerosis (ALS) through a systematic review and meta-analysis of randomized controlled trials and observational cohorts.
methodsA comprehensive search was conducted up to August 2025. Eligible studies included adults with SOD1-associated ALS treated with intrathecal tofersen. Outcomes were treatment-emergent adverse events (AEs), serious adverse events (SAEs), cerebrospinal fluid (CSF) abnormalities, and procedure-related complications. Pooled incidence rates with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models depending on heterogeneity. Risk of bias was assessed with MINORS, and certainty of evidence was graded using GRADE.
resultsSix studies (2 RCTs, 4 cohorts) comprising 179 patients receiving tofersen and 48 placebo controls were included. The pooled incidence of any AE was 98.0% (95% CI: 95.6–100), while SAEs occurred in 10.0% (95% CI: 0–22.1). Common adverse events included procedural pain (56.2%), headache (54.1%), back pain (38.4%), and extremity pain (35.9%). CSF pleocytosis was reported in 44.1% of patients, with high heterogeneity across studies. Gastrointestinal and constitutional events such as nausea (17.0%) and fatigue (21.6%) were usually mild. Respiratory failure occurred in 9.2% of cases. Most adverse events were manageable, though rare severe complications (e.g., meningitis, myelitis, intracranial hypertension) were described in individual reports.
conclusionTofersen is associated with frequent adverse events, predominantly mild to moderate, while serious complications are less common but clinically relevant. The overall safety profile supports its continued clinical use in SOD1-associated ALS, although long-term surveillance is warranted to better characterize rare outcomes.
Indexed as
Identifiers
41746412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.